BNGO vs. HBIO, SEER, AKYA, PRE, RPID, AXDX, OMIC, TLIS, ASTC, and HLTH
Should you be buying Bionano Genomics stock or one of its competitors? The main competitors of Bionano Genomics include Harvard Bioscience (HBIO), Seer (SEER), Akoya Biosciences (AKYA), Prenetics Global (PRE), Rapid Micro Biosystems (RPID), Accelerate Diagnostics (AXDX), Singular Genomics Systems (OMIC), Talis Biomedical (TLIS), Astrotech (ASTC), and Cue Health (HLTH). These companies are all part of the "analytical instruments" industry.
Harvard Bioscience (NASDAQ:HBIO) and Bionano Genomics (NASDAQ:BNGO) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.
Harvard Bioscience has higher revenue and earnings than Bionano Genomics. Harvard Bioscience is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
Harvard Bioscience has a net margin of -8.18% compared to Harvard Bioscience's net margin of -605.26%. Bionano Genomics' return on equity of 0.26% beat Harvard Bioscience's return on equity.
Harvard Bioscience has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Bionano Genomics has a beta of 2.33, indicating that its share price is 133% more volatile than the S&P 500.
Bionano Genomics has a consensus price target of $4.00, suggesting a potential upside of 365.82%. Given Harvard Bioscience's higher possible upside, analysts plainly believe Bionano Genomics is more favorable than Harvard Bioscience.
In the previous week, Harvard Bioscience had 5 more articles in the media than Bionano Genomics. MarketBeat recorded 6 mentions for Harvard Bioscience and 1 mentions for Bionano Genomics. Bionano Genomics' average media sentiment score of 1.52 beat Harvard Bioscience's score of 0.59 indicating that Harvard Bioscience is being referred to more favorably in the media.
Harvard Bioscience received 206 more outperform votes than Bionano Genomics when rated by MarketBeat users. Likewise, 72.02% of users gave Harvard Bioscience an outperform vote while only 64.80% of users gave Bionano Genomics an outperform vote.
80.9% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 9.0% of Harvard Bioscience shares are owned by company insiders. Comparatively, 1.7% of Bionano Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Harvard Bioscience beats Bionano Genomics on 12 of the 17 factors compared between the two stocks.
Get Bionano Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionano Genomics Competitors List
Related Companies and Tools
